KALY - Kali-Extracts Explores $50 Million Cannabis Biopharmaceutical Technology Sale
October 31 2019 - 07:54AM
InvestorsHub NewsWire
KALY – Kali-Extracts Explores $50
Million Cannabis Biopharmaceutical Technology Sale
Dallas, TX --
October 31, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced taking a next step with the
investor that has recently valued KALY’s biopharmaceutical
technology at $50 Million. The valuation has been presented
to KALY by an investor interested in acquiring KALY’s U.S. Patented
Cannabis Extraction Process and associated biopharmaceutical
research and developments. KALY management has asked the
investor to provide a “working” term-sheet for discussion
purposes. The proposed transaction has KALY maintaining
rights to its Patented Cannabis Extraction Process for business
pursuits other than pharmaceutical developments such as the
cannabis infused beverage and candy business it currently
conducts. KALY would also continue its CBD extraction
business provided to hemp cultivation operations. KALY
management considers the valuation consistent with Goldman Small Cap Research’s recent valuation,
but management maintains a position that the valuation still does
not reflect the full potential of its intellectual property.
KALY management wants to stay involved in the ongoing
biopharmaceutical developments even after a possible
sale.
KALY’s
intellectual property portfolio contains a deep pipeline of
cannabinoid product candidates including four distinct compounds
listed here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted
and the next phase of research now moving forward, KALY recently
filed for a new patent application specifically on its formulation
for symptoms associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition to KALY’s ongoing efforts to develop
prescription therapies, KALY has initiated a program to certify its
proprietary CBD extracts derived from KALY’s U.S. Patented
Extraction Process as an Over-The-Counter (OTC) drug under the
requirements prescribed by the U.S. Food and Drug
Administration.
Since the last biopharmaceuticals strategy update,
KALY has made substantial strides. KALY has since engaged
with a major university to initiate a next round of evaluations and
testing of its COPD treatment. The university program is
anticipated to kickoff soon and the company plans to issue periodic
updates as the program proceeds.
KALY has also made recent progress in advancing the
development of its other treatments. The advances have been
made possible by new partnerships. Announcements about the
new partnerships are coming soon.
To stay abreast
of the latest developments and learn more about the company visit
https://www.kali-extracts.com/.
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2023 to Mar 2024
Real-Time news about Kali Inc (CE) (OTCMarkets): 0 recent articles
More Kali, Inc. (PN) News Articles